Some studies link GLP-1 use to an increased risk for eye diseases but a recent paper argues there is insufficient evidence to ...

Learn about the use of GLP-1 agonists for weight loss and health improvement by celebrities like Oprah and Serena Williams.

As the patent for semaglutide nears its end, Novo Nordisk's dominance in the weight-loss market is being challenged. The ...

Definitive conclusions regarding the association between semaglutide and nonarteritic anterior ischemic optic neuropathy ...

The glucagon-like peptide-1 (GLP-1) receptor agonist gained accelerated approval for patients with MASH and moderate to ...

Semaglutide, the active ingredient in Ozempic and Wegovy, is a glucagon-like peptide-1 (GLP-1) receptor agonist taken as a ...

Serena Williams recently shared that she started taking the GLP-1 drug Zepbound after having her two children. The tennis ...

Participants on the 36 mg oral dose drop 12.4% of their body weight at 72 weeks, yet physicians warn of posttreatment weight ...

There is a low but increased risk of optic nerve disorders in patients with type 2 diabetes prescribed semaglutide or ...

New gene therapies that can come with a one-time cost of more than $2 million also are having an impact, insurance brokers ...

Millions of Americans who have dropped pounds and boosted their health using popular obesity drugs like Wegovy are facing a ...

As appetite-suppressing drugs change the way people eat, businesses are adapting to GLP-1 users by offering smaller portions ...